GLP-1 Weight Loss Drugs: Medical Guidance on Who Benefits Most

GLP-1 drugs, originally developed for diabetes management, have gained widespread attention for their weight loss properties. These medications work by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar levels. While they have demonstrated effectiveness in clinical settings, healthcare professionals stress that careful patient selection is essential for safe and beneficial outcomes.

Individuals most likely to benefit from GLP-1 medications are those with a body mass index exceeding 30, or those with a BMI of 27 or higher combined with weight-related health conditions such as type 2 diabetes, hypertension, or cardiovascular disease. These drugs are particularly effective for patients who have struggled with conventional weight loss methods and require additional therapeutic intervention. Medical professionals recommend these medications as part of a comprehensive treatment plan that includes dietary modifications and physical activity.

However, several groups should avoid GLP-1 drugs entirely. Individuals with a personal or family history of medullary thyroid cancer, those with multiple endocrine neoplasia syndrome type 2, and pregnant or breastfeeding women should not use these medications. Patients with severe gastrointestinal disorders, a history of pancreatitis, or certain thyroid conditions may also face contraindications. Additionally, those with unstable psychiatric conditions or a history of disordered eating patterns require careful evaluation before consideration.

Medical experts across South Asia recommend consulting qualified healthcare providers to determine individual suitability for GLP-1 therapy. The decision to prescribe these medications should be based on comprehensive medical assessment, consideration of potential side effects, and realistic expectations regarding weight loss outcomes. As access to these drugs increases in India and neighbouring countries, personalized medical guidance remains paramount for ensuring patient safety and treatment efficacy.